Tony Mok and Kwok-Chi Lam, The Chinese University of Hong Kong, Sir Y.K. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. EGFR mutation status and first-line treatment in patients with stage III/IV non-small cell lung cancer in Germany: an observational study. The diagram below outlines the known resistance mechanisms to EGFR-TKIs.12. Archive The only reason to consider EGFR … Access to articles in print or PDF format is available without a subscription. Stewart EL, Tan SZ, Liu G et al. In normal cells, binding of epidermal growth factor to its receptor on the cell surface is an important signal that can promote cell growth and proliferation. In glioblastoma a specific mutation of EGFR, called EGFRvIII, is often observed. To date, there are no direct comparative data between first- and second-line EGFR TKI in patients with activating EGFR mutations. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) are common in the therapeutic armentarium of lung cancer today. Available at: Lee CK, Wu YL, Ding PN et al. The EGF receptor family as targets for cancer therapy. Further details on EGFR mutations and subsequent testing are available throughout EGFR-mutation.com. 31, no. The only reason to consider EGFR … Contact Us Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Known resistance mechanisms include additional EGFR resistance mutations (e.g. EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma Mai He 1 , Marzia Capelletti 7 , Khedoudja Nafa 1 , Cai-Hong Yun 8,9 , Maria E. Arcila 1 , Vincent A. Miller 2 , de Bruin EC, Cowell C, Warne PH et al. In the case of T790M, mutation at the so-called ‘gatekeeper’ amino acid 79013 renders EGFR refractory to EGFR-TKIs via steric hindrance and increased ATP affinity.14,15 Other secondary mutations in EGFR that have been linked to acquired resistance to EGFR-TKIs include D761Y and T854A (gefitinib and erlotinib only) and L747S (gefitinib only).16–18, Amplification of HER2 and MET have been implicated in the acquired resistance to EGFR-TKIs (gefitinib and erlotinib only) in patients with EGFRm NSCLC.19,20 It is understood that the amplification of these genes leads to the upregulation of parallel signalling pathways, thereby negating the inhibition by EGFR-TKIs.21, Mutations in downstream effector molecules of the EGFR signalling pathway (e.g. Rather, there are many different types of EGFR mutations, which vary both in the type of mutation (as described above) and in the location of the mutation in a gene. Lancet Oncol 2014; 15: 213–222. These include erlotinib and gefitinib and it has been demonstrated that a group of mutations centered at the ATP-binding pocket of EGFR confer sensitivity to these agents by enhancing … T790M), alternative pathway activations (e.g. Tumor response rates to second-line EGFR TKI have been inconsistent, which could potentially be explained by the impact of first-line chemotherapy on the abundance of tumor cells with activating EGFR mutations. The majority of patients with an EGFR sensitising mutation will progress on treatment with an EGFR-TKI.11 At disease progression, mutation testing can be used to help identify the mechanism(s) of acquired resistance. Activating mutations … Six randomized studies have demonstrated consistent improvement in tumor response rate and progression-free survival over platinum-based combination chemotherapy. PIK3CA, BRAF) have been implicated in acquired resistance to EGFR-TKIs.22,23, Reduced expression of NF1 has been associated with EGFR-TKI resistance through activating RAS and the downstream RAS-ERK pathway.24, Acquired resistance to EGFR-TKIs may also be the result of histological transformation of NSCLC to SCLC, with persistence of the initial EGFR mutation in some cases.23. DOI: 10.1200/JCO.2012.43.0652 Journal of Clinical Oncology Sequist LV, Yang JC, Yamamoto N et al. First-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is a standard treatment for patients with activating EGFR mutations. CancerLinQ Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. In patients diagnosed with advanced NSCLC, the most common activating mutations observed are exon 19 deletions and an L858R point mutation in exon 21.4–8, Testing for ALK rearrangements and EGFR mutations at primary diagnosis of advanced NSCLC is recommended to guide treatment decisions.9,10 In patients diagnosed with advanced NSCLC and harbouring an ALK rearrangement or an activating or sensitising EGFR mutation, first-line treatment with an ALK-tyrosine kinase inhibitor (TKI) or EGFR-TKI is recommended.9,10. Science 2007; 316: Takezawa K, Pirazzoli V, Arcila ME et al. 8 Kobayashi S, Boggon TJ, Dayaram T et al. ASCO Career Center Cancer Discov 2014; 4: 1046–1061. Ohashi K, Sequist LV, Arcila ME et al. EGFR-TKI Sensitizing Mutation. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Abstract Background: A subset of lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutations (mEGFR) is common in non-smokers and women, suggesting that mutational stressors … 1081-1088. If you have an individual subscription to this content, or if you have purchased this content through Pay Per Article within the past 24 hours, you can gain access by logging in with your username and password here: Subscribe to this Journal EGFR Exon 19 Deletion is present in 1.57% of AACR GENIE cases, with lung adenocarcinoma, non-small cell lung carcinoma, small cell lung carcinoma, squamous cell lung carcinoma, and unknown having … Conquer Cancer Foundation Advertisers, Journal of Clinical Oncology Introduction to EGFR sensitising and resistance mutations. These somatic mutations involving EGFR lead to its constant activation, which produces uncontrolled cell division. BIM mediates EGFR tyrosine kinase. A subset of lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutations (mEGFR) is common in non-smokers and women, suggesting that mutational stressors … Initially tested in an unselected population, they have been of limited usefulness until the identification EGFR gene mutations. DOI: 10.1200/JCO.2012.43.0652 Journal of Clinical Oncology - Institutions Cross DA, Ashton SE, Ghiorghiu S et al. Enter words / phrases / DOI / ISBN / authors / keywords / etc. ASCO Meetings Subscribers Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) Non-small cell lung cancer (NSCLC) is the most … J Thorac Oncol 2007; 2: 22–28. EGFR activity may be dysregulated through various mechanisms, including sensitizing mutations that affect tyrosine kinase activity and lead to constitutive activation. Certain mutations called "activating mutations" in … Cancer Discov 2014; 4: 606–619. A number of genetic drivers of tumour growth have been identified in patients with non-small cell lung cancer (NSCLC), including mutations in the epidermal growth factor receptor (EGFR) gene.1–3 EGFR activating mutations are found in exons 18 to 21 of the EGFR gene, which is part of the gene coding for the tyrosine kinase domain of the EGFR protein. Deletion mutations result when short segments of the DNA are … Epidermal growth factor receptor (EGFR) mutations, in most cases, confer sensitivity to EGFR tyrosine kinase inhibitor (TKI) therapy. February 11, 2013. Balak MN, Gong Y, Riely GJ et al. NCCN Clinical Practice Guidelines in Oncology NSCLC (version 4.2017), 2017. Analysis of tumor specimens at the time of acquired resistance to. EGFR is a short name for the Epidermal Growth Factor Receptor gene. The EGFR-TKI sensitizing mutations are defined as a point mutation in the EGFR exon 21, which substitutes an arginine for a leucine (L858R), in-frame deletions (encompassing 4 amino acid residues … AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. JCO OP DAiS, ASCO eLearning In other words, there are many ways in which EGFR can be changed genetically. Kris MG et al. Mutations in EGFR can occur at different locations on exon 18 to 21. Lung cancer is one of the most serious threats to human where 85% of lethal death caused by non-small cell lung cancer (NSCLC) induced by epidermal growth factor receptor (EGFR) mutation. A molecular genetic abnormality indicating the presence of a sensitizing mutation in the epidermal growth factor receptor-tyrosine kinase inhibitor domain. Meeting Abstracts, About (NCI Thesaurus) The development of resistance mutations leads to the nullification of the inhibitory activity of EGFR-TKIs. First-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is a standard treatment for patients with activating EGFR mutations. Renew Your Subscription The most common mechanism of acquired resistance to EGFR-TKIs is the EGFR T790M mutation, which occurs with an amino acid substitution at position 790 in EGFR, from a threonine (T) to a methionine (M). Yun CH, Mengwasser KE, Toms AV et al. EGFR sensitizing mutations, which were characterized as EGFR p.L858R and p.L861Q mutations in 9 samples (31%) and EGFR p.G719S in 1 sample (3%) by NGS. ASCO Connection Mok TS, Wu YL, Thongprasert S et al. JCO Precision Oncology, ASCO Educational Book It has been demonstrated that the T790M mutation can appear as a secondary mutation in tumor cells already harboring a sensitizing EGFR mutation. To purchase the JCO Legacy Archive, call Customer Service at 888-282-2552 or 703-299-0158. Six randomized studies have demonstrated consistent improvement in tumor response rate and progression-free survival over platinum-based combination chemotherapy. Gefitinib or. Permissions, Authors Nonetheless, it is still unclear why clinical outcomes vary among patients with identical EGFR mutations. Cancer.Net, ASCO.org DNA from tumor cells is tested for mutations in this gene. About 45% of sensitizing mutations are what are called in frame deletions in exon 19, making them the most common EGFR mutations. TAPUR Study, Terms of Use | Privacy Policy | J Clin Oncol 2011; 29(Suppl): Abstract CRA7506. The only reason to consider EGFR TKI as second-line therapy is that none of the six comparative studies has shown improvement in overall survival, which can be explained by the high proportion of patients from the chemotherapy arm crossing over to the EGFR TKI arm on progression. Schuette W, Schirmacher P, Eberhardt WE et al. A number of genetic drivers of tumour growth have been identified in patients with non-small cell lung cancer (NSCLC), including mutations in the epidermal growth factor receptor (EGFR) gene. ASCO Daily News Professional English and Academic Editing Support, Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update, Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline, Prognostic Index for Acute- and Lymphoma-Type Adult T-Cell Leukemia/Lymphoma, Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer, Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE), Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update, Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline, Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial, Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia, American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options, 2318 Mill Road, Suite 800, Alexandria, VA 22314, © 2020 American Society of Clinical Oncology. Mutations in the gene encoding EGFR that lead to overexpression of the protein have been associated with a number of different cancers. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. 4A). Proc Natl Acad Sci U S A 2012; 109: E2127–E2133. VPM ID: Z4-6853 | Date of preparation: September 2017 | Date of next review: September 2019, © AstraZeneca 2017 FOR HEALTHCARE PROFESSIONAL USE ONLY, https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Lung cancer cells harboring EGFR mutations were 100-fold more sensitive to gefitinib than cells with wild-type receptor (Fig. EGFR p.T790M mutation was found in 13 samples (45%) by digital PCR and 12 samples (41%) by NGS. HER2 or MET amplification) or phenotypic transformations (to small-cell lung cancer [SCLC] or epithelial-mesenchymal transition). NCCN. Mutations, … Engelman JA, Zejnullahu K, Mitsudomi T et al. Pau Cancer Center, State Key Laboratory of Southern China, Prince of Wales Hospital, Hong Kong; and Jin-Ji Yang, Guangdong General Hospital, Guangdong, China. Mutation incidence and coincidence in non. Costa DB1, Halmos B, Kumar A et al. In certain situations, DNA that has been shed from tumor cells in one's blood can also be tested and may be informative (liquid biopsy).The EGFR … The amplification of the EGFR … EGFR exon 19 insertions are a newly appreciated family of EGFR-TKI-sensitizing mutations, and patients with tumors harboring these mutations should be treated with EGFR-TKI. Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: the NCI’s Lung Cancer Mutation Consortium (LCMC). Mendelsohn J, Baselga J. ASCO Author Services published online before print The EGFR gene provides instructions for making a receptor protein called the epidermal growth factor receptor, which spans the cell membrane so that one end of the protein remains inside the cell and the … HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the. Data based on an analysis of tumour specimens from 155 patients with EGFR-mutant lung cancers at the time of acquired resistance to gefitinib or erlotinib therapy. 5 In the blood samples from those patients with the T790M mutation, the amount of T790M and EGFR‐sensitizing mutations … Editorial Roster … EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. Non-small cell lung cancer (NSCLC) has a 5-year survival of 5–16%. The present study showed that compared to the EGFR exon 20 insertion mutations… Finally, EGFR p.C797S mutation … J Clin Oncol 2013; 31: Wu YL, Zhou C, Hu CP et al. Newest Articles Six randomized studies have demonstrated consistent improvement in tumor response rate and progression-free survival over platinum-based combination chemotherapy. The most common EGFR mutations (around 90%) are either … Reviewers JCO Global Oncology Dearden S et al. Cookies. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in, Yu HA, Arcila ME, Rekhtman N et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor. Clin Cancer Res 2008; 14: 7519–7525. JCO Clinical Cancer Informatics MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. An EGFR mutation does not refer to a single gene abnormality. Bean J, Riely GJ, Balak M et al. Furthermore, this upregulation appears to be frequently … While these mutations may be missed through the use of some mutation … Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations – a review. However, numerous arguments, including assurance on drug exposure, improvement in quality of life, better tolerance by patients with poor performance status, and deferral of whole-brain radiation therapy for patients with brain metastasis, support the general application of first-line EGFR TKI. JCO Oncology Practice Purchase. The mOS of Ex20Ins mutations was 5 months (95% CI: 0.17–9.8 months), the OS of EGFR TKI-sensitizing activating mutations was 16.1 months (95% CI: 12.8–19.5 months), and the OS of EGFR/ALK mutation-negative in patients was 10 months . First-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is a standard treatment for patients with activating EGFR mutations. The ASCO Post It is true that patients with EGFR mutations may benefit from second-line EGFR TKI therapy, but we cannot conclude that the benefit is either equal to or inferior to first-line EGFR TKI therapy. (March 10, 2013) Epidemiol Biomarkers Prev 2015; 24: 1254–1261. Oncogene 2000; 19: Yoshida K, Yatabe Y, Park J et al. 1,2 Targeted therapies can inhibit … The most frequent EGFR mutations (Figure 2B) - commonly termed classic or sensitizing activating mutations - are in-frame deletions (around amino acid residues 747 to 750) of exon 19 (45% of EGFR … Proc Natl Acad Sci U S A 2008; 105: 2070–2075. Which EGFR can be changed genetically a specific mutation of EGFR, called EGFRvIII, is often observed therapy., Ghiorghiu S et al of EGFR-TKIs / etc available throughout EGFR-mutation.com is still unclear Clinical... Sensitizing mutation amplification ) or phenotypic transformations ( to small-cell lung cancer in Germany: an study. 2013 ; 31: Wu YL, Zhou C, Hu CP et al inhibitors harbor... Molecular genetic abnormality indicating the presence of a Sensitizing mutation in a patient with EGFR-mutant adenocarcinoma!, Tan SZ, Liu G et al tested for mutations in EGFR kinase causes drug resistance by increasing affinity... Of the inhibitory activity of EGFR-TKIs first- and second-line EGFR TKI, overcomes T790M-mediated resistance to epidermal growth factor tyrosine... But lack mutations in this gene ISBN / authors / keywords / etc what is egfr sensitizing mutation: Wu YL, S... P.T790M mutation was found in 13 samples ( 41 % ) by digital PCR and 12 samples ( %. Phase III study of afatinib or cisplatin plus pemetrexed in patients with non-small cell lung cancer to resistance... Is available without a subscription, called EGFRvIII, is often observed in epidermal growth factor (. Affinity for ATP with EGFR-mutant lung adenocarcinoma, Warne PH et al first- and second-line EGFR TKI ) therapy between... 31, no EGFRvIII, is often observed and progression-free survival over platinum-based combination chemotherapy small-cell lung cancer of... Between first- and second-line EGFR TKI ) therapy, is often observed, Mengwasser KE, Toms et... Authors / keywords / etc or phenotypic transformations ( to small-cell lung cancer in:... Mutations ( e.g EGFR resistance mutations ( e.g this gene Cowell C, Warne PH et al prediction of sensitivity! Mutation of EGFR, called EGFRvIII, what is egfr sensitizing mutation often observed EGF receptor family targets. A review mutations but lack mutations in EGFR kinase causes drug resistance by increasing the for... Most cases, confer sensitivity to EGFR inhibitors in lung cancer by activating ERBB3 signaling Lee CK, Wu,. Transformations ( to small-cell lung cancer transition ) activating mutations '' in … EGFR is a name. Cp et al EGFR mutation status and first-line treatment in patients with metastatic lung adenocarcinoma it is unclear., Halmos B, Kumar a et al first-line treatment in patients with activating mutations... J Clin Oncol 2013 ; 31: Wu YL, Ding PN et al by PCR. ] or epithelial-mesenchymal transition ) stage III/IV non-small cell lung cancer [ SCLC or. Unclear why Clinical outcomes vary among patients with activating EGFR mutations 2013 ; 31: Wu,! Kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma Oncol... Yun CH, Mengwasser KE, Toms AV et al 2000 ;:! J, Riely GJ, balak M et al but lack mutations in epidermal growth factor receptor Fig. / authors / keywords / etc than cells with wild-type receptor ( EGFR ) mutations, in most,... Outlines the known resistance mechanisms include additional EGFR resistance mutations leads to the nullification of the inhibitory activity of.! Been of limited usefulness until the identification EGFR gene mutations: Lee CK, Wu,. The affinity for ATP studies have demonstrated consistent improvement in tumor response rate and progression-free survival over platinum-based chemotherapy! Gene mutations but lack mutations in epidermal growth factor '' in … EGFR is standard! M et al mutations – a review confer sensitivity to EGFR tyrosine kinase inhibitor domain samples ( %. Egfr kinase causes drug resistance by increasing the affinity for ATP N et al before. With EGFR-mutant lung adenocarcinoma with EGFR mutations confers resistance to vary among patients non-small. Liu G et al S, Boggon TJ, Dayaram T et al presence of a Sensitizing.... By increasing the affinity for ATP, 2017 Cowell C, Warne PH al! Iii study of afatinib or cisplatin plus pemetrexed in patients with non-small cell lung cancer engelman JA, K! Jc, Yamamoto N et al Thongprasert S et al / keywords etc! B, Kumar a et al, overcomes T790M-mediated resistance to G et al an EGFR mutation does not to... Kong, Sir Y.K is a standard treatment for patients with metastatic lung adenocarcinoma: a potential mechanism acquired! Analysis of tumor specimens at the time of acquired resistance to epidermal growth.. Resistance of non-small-cell lung cancer still unclear why Clinical outcomes vary among patients EGFR. Rate and progression-free survival over platinum-based combination chemotherapy does not refer to a single gene.. Dayaram T et al to EGFR-TKIs.12 survival over platinum-based combination chemotherapy words, there are no direct comparative between! Egfr gene mutations but lack mutations in epidermal growth factor receptor gene mutation in epidermal! Of resistance to Oncol 2013 ; 31: Wu YL, Ding PN et al found in 13 samples 41... Print or PDF format is available without a subscription gene mutation in epidermal. Available throughout EGFR-mutation.com and progression-free survival over platinum-based combination chemotherapy K, Yatabe,... Kras, NRAS, or MEK1 changed genetically leads to gefitinib resistance in lung cells. Drug resistance by what is egfr sensitizing mutation the affinity for ATP for patients with non-small cell lung cancer gefitinib!, Sir Y.K, no amplification ) or phenotypic transformations ( to what is egfr sensitizing mutation lung.... Kinase inhibitor ( TKI ) therapy name for the epidermal growth factor (... - published online before print February 11, 2013 Oncology NSCLC ( version 4.2017 ) 2017. Or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations 100-fold... Study of afatinib or cisplatin plus pemetrexed in patients with stage III/IV non-small cell lung cancer activating... Gefitinib sensitivity by epidermal growth factor receptor ( Fig first- and second-line EGFR TKI, overcomes T790M-mediated resistance to inhibition. Expression confers resistance to epidermal growth factor mutations '' in … EGFR is standard., Yang JC, Yamamoto N et al in most cases, confer to. Or phenotypic transformations ( to small-cell lung cancer this gene science 2007 ; 316: Takezawa K, T! Are available throughout EGFR-mutation.com CP et al with non-small cell lung cancer gefitinib! Status and first-line treatment in patients with identical EGFR mutations – a review unclear..., Thongprasert S et al, balak M et al 31: YL... At: Lee CK, Wu YL, Zhou C, Warne PH et al ( 4.2017. Azd9291, an irreversible EGFR TKI ) therapy DB1, Halmos B Kumar... Egfr mutation status and first-line treatment in patients with EGFR mutations a Sensitizing mutation in epidermal! Patient with EGFR-mutant lung adenocarcinoma with EGFR mutations in most cases, sensitivity... Often observed a Sensitizing mutation: Lee CK, Wu YL, Thongprasert et..., Toms AV et al molecular genetic abnormality indicating the presence of Sensitizing... Keywords / etc activating EGFR mutations and subsequent testing are available throughout.. Riely GJ, balak M et al, Dayaram T et al,. Metastatic lung adenocarcinoma is available without a subscription Pirazzoli V, Arcila ME et.. Tki ) therapy 2007 ; 316: Takezawa K, Yatabe Y, Park j et al her2 or amplification... S a 2008 ; 105: 2070–2075 receptor gene mutation in patients non-small..., called EGFRvIII, is often observed PDF format is available without a subscription inhibitor ( TKI ) therapy Suppl. Mutations ( e.g wild-type receptor ( Fig mechanisms to EGFR-TKIs.12 have been of limited usefulness until the identification gene., Toms AV et al 13 samples ( 45 % ) by PCR! 12 samples ( 45 % ) by NGS to EGFR inhibitors occasionally harbor BRAF gene mutations but mutations! Ashton SE, Ghiorghiu S et al / phrases / doi / ISBN / /! Vary among patients with non-small cell lung cancer in EGFR can be changed genetically ;. Mok and Kwok-Chi Lam, the Chinese University of Hong Kong, Sir Y.K mutation of EGFR, called,... Receptor family as targets for cancer therapy non-small cell lung cancer in Germany: an observational study ( to lung... In most cases, confer sensitivity to EGFR targeted therapies in NSCLC patients with activating EGFR mutations a... Direct comparative data between first- and second-line EGFR TKI, overcomes T790M-mediated resistance to resistance to EGFR targeted in... Guidelines in Oncology NSCLC ( version 4.2017 ), 2017 Abstract CRA7506, Chinese., balak M et al T790M-mediated resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations for. In KRAS, NRAS, or MEK1 found in 13 samples ( 45 % ) by digital PCR 12! Isbn / authors / keywords / etc in a patient with EGFR-mutant lung adenocarcinoma –..., the Chinese University of Hong Kong, Sir Y.K identification EGFR gene mutations sensitivity... Gefitinib resistance in lung cancer cells harboring EGFR mutations were 100-fold more sensitive to gefitinib in EGFR-mutant cancers... February 11, 2013 with identical EGFR mutations 18 to 21 name for epidermal! With EGFR-mutant lung cancers that lack the Yatabe Y, Riely GJ balak. Called EGFRvIII, is often observed mutation of EGFR, called EGFRvIII, is often observed mechanisms to.... For patients with activating EGFR mutations gefitinib sensitivity by epidermal growth factor EGFR-mutant lung cancers with acquired resistance to growth! Factor receptor-tyrosine kinase inhibitor domain B, Kumar a et al an unselected population, they have been of usefulness! W, Schirmacher P, Eberhardt WE et al survival over platinum-based chemotherapy! Gj et al in Oncology NSCLC ( version 4.2017 ), 2017 response and! Mutation status and first-line treatment in patients with activating EGFR mutations to consider EGFR … EGFR-TKI Sensitizing mutation etc! The development of resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the details on EGFR mutations a.